Hanna, D., Merrick, S., Ghose, A. et al. (24 more authors) (2024) Real world study of sacituzumab govitecan in metastatic triple-negative breast cancer in the United Kingdom. British Journal of Cancer, 130 (12). pp. 1916-1920. ISSN 0007-0920
Abstract
Background
Treatment options for pre-treated patients with metastatic triple-negative breast cancer (mTNBC) remain limited. This is the first study to assess the real-world safety and efficacy of sacituzumab govitecan (SG) in the UK.
Methods
Data was retrospectively collected from 16 tertiary UK cancer centres. Pts had a diagnosis of mTNBC, received at least two prior lines of treatment (with at least one being in the metastatic setting) and received at least one dose of SG.
Results
132 pts were included. Median age was 56 years (28–91). All patients were ECOG performance status (PS) 0-3 (PS0; 39, PS1; 76, PS2; 16, PS3;1). 75% (99/132) of pts had visceral metastases including 18% (24/132) of pts with CNS disease. Median PFS (mPFS) was 5.2 months (95% CI 4.5–6.6) with a median OS (mOS) of 8.7 months (95% CI 6.8-NA). The most common adverse events (AEs) were fatigue (all grade; 82%, G3/4; 14%), neutropenia (all grade; 55%, G3/4; 29%), diarrhoea (all grade; 58%, G3/4, 15%), and nausea (all grade; 38%, G3/4; 3%). SG dose reduction was required in 54% of pts.
Conclusion
This study supports significant anti-tumour activity in heavily pre-treated pts with mTNBC. Toxicity data aligns with clinical trial experience.
Metadata
Item Type: | Article |
---|---|
Authors/Creators: |
|
Copyright, Publisher and Additional Information: | © The Author(s) 2024. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http:// creativecommons.org/licenses/by/4.0/. |
Keywords: | Biomedical and Clinical Sciences; Oncology and Carcinogenesis; Cancer; Women's Health; Breast Cancer; Patient Safety; Clinical Research; Clinical Trials and Supportive Activities; Evaluation of treatments and therapeutic interventions; Pharmaceuticals; Cancer; Humans; Triple Negative Breast Neoplasms; Middle Aged; Female; Aged; Antibodies, Monoclonal, Humanized; Adult; United Kingdom; Camptothecin; Retrospective Studies; Aged, 80 and over; Neoplasm Metastasis; Immunoconjugates |
Dates: |
|
Institution: | The University of Leeds |
Academic Units: | The University of Leeds > Faculty of Medicine and Health (Leeds) > School of Medicine (Leeds) > Leeds Institute of Medical Research (LIMR) > Division of Oncology |
Funding Information: | Funder Grant number Cancer Research UK Supplier No: 138573 C37059/A12513 Cancer Research UK Supplier No: 138573 C37059/A12513 Cancer Research UK Supplier No: 138573 C37059/A12513 Cancer Research UK Supplier No: 138573 C37059/A12513 Cancer Research UK Supplier No: 138573 C37059/A11941 Cancer Research UK Supplier No: 138573 C37059/A11941 Cancer Research UK Supplier No: 138573 C37059/A12514 Cancer Research UK Supplier No: 138573 C37059/A12514 Cancer Research UK Supplier No: 138573 C64904/A27744 Cancer Research UK Supplier No: 138573 C7852/A19772 |
Depositing User: | Symplectic Publications |
Date Deposited: | 11 Jul 2024 11:58 |
Last Modified: | 11 Jul 2024 11:58 |
Published Version: | https://www.nature.com/articles/s41416-024-02685-9 |
Status: | Published |
Publisher: | Springer |
Identification Number: | 10.1038/s41416-024-02685-9 |
Related URLs: | |
Open Archives Initiative ID (OAI ID): | oai:eprints.whiterose.ac.uk:214663 |